Drug Trial Radar · NCT07756580
A Study to Evaluate Sequential Administration of Injections of AGN-151586 Followed by BOTOX in Adult Participants for Treatment of Glabellar Lines
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
143
Actual
Start
Aug 10, 2026
Primary completion
Feb 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Aug 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin. The purpose of this study is to assess how safe and effective sequential administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) is in adult participants with moderate to severe GL. AGN-151586 is an investigational drug being developed for treatment of moderate to severe glabellar lines. Participants are placed into 1 of 2 groups called treatment arms. In both arms participants will receive both AGN-151586 and BOTOX. Approximately 120 adult participants with moderate to severe glabellar lines enrolled in the study in approximately 8 sites around the United States. Participants will receive injections of AGN-151586 on Day 1 in the glabellar complex. After meeting treatment criteria, participants in Cohort 1 will receive intramuscular injections of BOTOX on Day 14, and participants in Cohort 2 will receive intramuscular injections of BOTOX on Day 21. Participants will be followed for up to approximately 141 days.
Conditions
- Glabellar Lines
Interventions
AGN-151586Drug
Injection
BOTOXDrug
Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately Day 141
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Advanced Research Associates - Glendale /ID# 283833
Glendale, Arizona
Eye Research Foundation /ID# 283835
Newport Beach, California
Pacific Clinical Innovations /ID# 283812
Vista, California
Etre, Cosmetic Dermatology And Laser Center /ID# 283831
New Orleans, Louisiana
Skincare Physicians /ID# 283851
Chestnut Hill, Massachusetts
Wilmington Dermatology Center /ID# 283853
Wilmington, North Carolina
Tennessee Clinical Research Center /ID# 283894
Nashville, Tennessee
Austin Institute for Clinical Research - Pflugerville /ID# 283817
Pflugerville, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.